Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Resources
  • Blog

Revvityブログ

発見から治療までのイノベーションを促進

Latest

Small nuclear RNAs: biogenesis, function, and NGS-based study techniques.

NGS September 16, 2025 - 5 min read
Read
Drug Development, Disease Research

The significance of longitudinal in vivo imaging in advancing drug discovery.

November 8, 2024 - 3 min read
Read
Cancer

Fluorescence imaging is comparable to PET in early detection of tumor metabolism.

April 25, 2024 - 4 min read
Read
Cancer, Drug Development, Disease Research

Why use fluorescent probes in your in vivo imaging studies?

April 9, 2024 - 3 min read
Read
Cancer

Imaging cell death to validate novel anti-cancer treatments.

April 3, 2024 - 3 min read
Read
Disease Research, Drug Development

Seven steps to designing an effective in vivo fluorescence imaging study.

April 3, 2024 - 2 min read
Read
Cancer

Illuminating cancer research: what tumor burden alone can’t tell you.

April 3, 2024 - 3 min read
Read
Metabolic research, Drug Development

In vivo imaging study highlights potential for non-invasive evaluation of NASH.

April 3, 2024 - 2 min read
Read

ご質問がございましたら、
お気軽にお問い合わせください。

お問合せ
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.